"Over the last few years, we have invested significantly in our manufacturing and processing technologies," said David Holmes, founder and president of Pharmachem. "Our venture with PNI will help us do a better job of marketing new ingredients and processes resulting from those technologies."
The venture will in turn enhance PNI's ability to launch new ingredients to add to brands including the Cran-Max cranberry extract, InoCell Natural Protection, and Celadrin Joint Flexibility and Pain Relief.
"With the tremendous production capability and scientific know-how of Pharmachem, we will be able to launch more ingredients, more quickly," said Dean Mosca, founder and president of PNI. "Because of Pharmachem's superior research capabilities, we will also be able to identify many new potential ingredients."
Pharmachem has been expanding its manufacturing and processing technology with the acquisitions of Anaheim-based American Ingredients, the Avoca customized manufacturing and extraction facility, and MPT, a facility with fluidized bed and high-sheer granulation technologies in Paterson, NJ.